The National Institute for Health and Care Excellence

Our first guideline on kidney cancer recommends better use of biopsies to avoid surgery

The NICE guideline recommends offering a biopsy to help confirm the diagnosis and inform treatment options for people with suspected renal cell carcinoma (RCC), where the cancer has not spread (known ...
The National Institute for Health and Care Excellence

Hundreds of people set to benefit after life-extending lung cancer treatment given green light

Targeted immunotherapy found to significantly increase overall survival rates for people with an aggressive form of lung cancer has been recommended by NICE. People with an aggressive form of lung ...
The National Institute for Health and Care Excellence

Fertility clinics must end unproven treatments that don't help couples have babies

Fertility clinics should not offer unproven treatments that don't help people have babies, our independent committee has recommended in draft guidance.
National Institute for Health and Care Excellence

Osimertinib with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancer

There is a commercial access agreement for osimertinib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...
National Institute for Health and Care Excellence

Leniolisib for treating activated phosphoinositide 3-kinase delta syndrome in people 12 years and over

There is a simple discount patient access scheme for leniolisib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...
National Institute for Health and Care Excellence

Efanesoctocog alfa for treating and preventing bleeding episodes in haemophilia A in people 2 years and over

There is a simple discount patient access scheme for efanesoctocog alfa. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...
National Institute for Health and Care Excellence

Anhydrous sodium thiosulfate for preventing hearing loss caused by cisplatin chemotherapy in people 1 month to 17 years with localised solid tumours

There is a simple discount patient access scheme for anhydrous sodium thiosulfate. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can ...
National Institute for Health and Care Excellence

Elranatamab for treating relapsed and refractory multiple myeloma after 3 or more treatments

Evidence-based recommendations on elranatamab (Elrexfio) for treating relapsed and refractory multiple myeloma after 3 or more treatments in adults. Next review: More evidence on elranatamab is being ...
National Institute for Health and Care Excellence

Teclistamab for treating relapsed and refractory multiple myeloma after 3 or more treatments

There is a simple discount patient access scheme for teclistamab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...
National Institute for Health and Care Excellence

Quizartinib for induction, consolidation and maintenance treatment of newly diagnosed FLT3-ITD-positive acute myeloid leukaemia

There is a simple discount patient access scheme for quizartinib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...
National Institute for Health and Care Excellence

Faricimab for treating visual impairment caused by macular oedema after retinal vein occlusion

There is a simple discount patient access scheme for faricimab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...
National Institute for Health and Care Excellence

Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma

There is a commercial access agreement for pembrolizumab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact keiron.hughes@msd.com ...